CHOLERA TOXIN CHIMERA AND ITS USE AS A STAPH VACCINE

• US 20180028638A9
• Filed: 08/11/2014
• Published: 02/01/2018
• Est. Priority Date: 12/16/2011
• Status: Active Grant

• Current Assignee: Boise State University
• Original Assignee: Boise State University
• Inventors: Tinker, Juliette
• Granted Patent: US 9,943,582 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 2039/543 intranasal
• CPC Class Codes: A61K 2039/552 Veterinary vaccine
• CPC Class Codes: A61K 2039/55516 Proteins; Peptides
• CPC Class Codes: A61K 2039/575 humoral response
• CPC Class Codes: A61K 2039/6037 Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
• CPC Class Codes: A61K 39/085 Staphylococcus
• CPC Class Codes: A61K 39/107 Vibrio
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 14/245 Escherichia (G)
• CPC Class Codes: C07K 14/25 Shigella (G)
• CPC Class Codes: C07K 14/28 from Vibrionaceae (F)
• CPC Class Codes: C07K 14/31 from Staphylococcus (G)
• CPC Class Codes: C07K 14/315 from Streptococcus (G), e.g. Enterococci
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: Y10S 424/823 Bacterial vaccine for bovine species, e.g. cattle
• CPC Class Codes: Y10S 424/828 Bacterial vaccine for canidae or mustelidae, e.g. dogs, foxes, minks
• CPC Class Codes: Y10S 424/829 Bacterial vaccine for equine species, e.g. horses
• CPC Class Codes: Y10S 530/825 Bacteria

Abstract

The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of Staphylococcus aureus. One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of: an antigenic material from S. aureus and an antigenic material from a S. aureus-specific polypeptide.

Claims

1. An S. aureus specific polypeptide antigen comprising a truncated iron-regulated surface determinant A (IsdA).

2. The S. aureus specific polypeptide antigen of claim 1 having a sequence of SEQ ID NO:

4 or a protein with 90% homology thereto.

3. The protein of claim 1, wherein said (IsdA) protein comprises the amino acid sequence as set forth in SEQ ID NO:

5 or SEQ ID NO;

6.

4. A chimeric protein comprising the antigen of claim 1 and an adjuvant protein.

5. The chimeric protein of claim 4 comprising SEQ ID NO:

4 or a protein with 90% homology thereto.

6. The chimeric protein of claim 5 wherein said adjuvant is selected form the group consisting of:

a portion of cholera toxin, a portion of heat labile toxin, or a portion of shiga toxin.

7. The chimeric protein of claim 6 wherein said adjuvant is cholera toxin subunit A or B, heat labile toxin subunit B, or Shiga toxin subunit B.

8. The chimeric protein of claim 7 wherein said adjuvant is cholera toxin adjuvant protein is CTA₂ or CTB.

9. The chimeric protein of claim 5 wherein the chimeric protein is assembled from a first polypeptide and a second polypeptide that are non-covalently linked.

10. The chimeric protein of claim 5 wherein the chimeric protein is a fusion protein.

11. The chimeric protein of claim 8 comprising a sequence of SEQ ID NO:

2, 3, 5, or 6, or a sequence with 90% homology thereto.

12. An immunogenic composition comprising the chimeric protein of claim 1 and a carrier.

13. The immunogenic composition of claim 12 further comprising an adjuvant protein.

14. The immunogenic composition of claim 13 wherein said adjuvant is selected form the group consisting of:

a portion of cholera toxin, a portion of heat labile toxin, or a portion of shiga toxin.

15. The immunogenic composition of claim 14 wherein said adjuvant is cholera toxin subunit A or B, heat labile toxin subunit B, or Shiga toxin subunit B.

16. The immunogenic composition of claim 15 wherein said adjuvant is cholera toxin adjuvant protein is CTA₂ or CTB.

17. The immunogenic composition of claim 16 wherein said cholera toxin adjuvant has a sequence of SEQ ID NO:

2 or 3 or a sequence with 90% homology thereto.

18. The immunogenic composition of claim 13 wherein the chimeric protein is assembled from a first polypeptide and a second polypeptide that are non-covalently linked.

19. The immunogenic composition of claim 13 wherein the chimeric protein is a fusion protein.

20. The immunogenic composition of claim 13 having a sequence of SEQ ID NO:

5 or SEQ H) NO;

6, or a sequence with 90% homology thereto.